Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-010-1141-3PMID 20809360
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial)

  2010cited by this paper
• Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.

  2009cited by this paper
• Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study

  2009cited by this paper
• Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland.

  2009influential reference
• Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer

  2009cited by this paper
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

  2009influential reference
• STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells

  2008influential reference
• Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.

  2007cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2007cited by this paper
• Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.

  2007cited by this paper
• Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.

  2007cited by this paper
• Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.

  2006cited by this paper
• Changes in the hormone receptors of human breast carcinoma xenografts in nude mice by treatment with cytotoxic agents

  2006cited by this paper
• What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及

  2006cited by this paper
• Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice

  2006cited by this paper
• The role of aromatase and 17-β-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer

  2006influential reference
• Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

  2005cited by this paper
• Serum testosterone levels and breast cancer recurrence

  2005cited by this paper
• Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.

  2005cited by this paper
• Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

  2005cited by this paper
• Human Epidermal Growth Factor Receptor 2 Status Modulates Subcellular Localization of and Interaction with Estrogen Receptor α in Breast Cancer Cells

  2004cited by this paper
• A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group

  2004cited by this paper
• Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects

  2001cited by this paper
• Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

  2000cited by this paper
• Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.

  2000cited by this paper
• Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan.

  1999cited by this paper
• Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

  1998cited by this paper
• A new tool for efficient transfection of dog and human thyrocytes in primary culture.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

  1998cited by this paper
• Testing strategies in multi-dose experiments including active control.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells.

  1997cited by this paper
• The relevance of preclinical models to the treatment of postmenopausal breast cancer.

  1997cited by this paper
• Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.

  1996cited by this paper
• Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

  1992cited by this paper
• Expression of estrogen receptor and its messenger ribonucleic acid in the MCF-7 cell line: multiparametric analysis of its processing and regulation by estrogen.

  1990cited by this paper
• Intratumoral aromatase as a prognostic factor in human breast carcinoma.

  1989cited by this paper
• Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs.

  1989cited by this paper
• The hormonal basis of reproductive defects in athymic mice: diminished gonadotropin concentrations in prepubertal females.

  1981cited by this paper
• A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

  1977cited by this paper
• (Note) An Improved Method of Producing Hormone-Cholesterol Pellets

  1964cited by this paper

• Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer

  2025cites this paper
• Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens

  2025cites this paper
• Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer

  2025cites this paper
• Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial

  2025cites this paper
• Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration resistant prostate cancer：A retrospective, real-world study.

  2024cites this paper
• Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle?

  2024cites this paper
• Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

  2023cites this paper
• Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer

  2022cites this paper
• Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

  2020cites this paper
• The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis

  2020cites this paper
• Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer

  2019cites this paper
• Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer

  2019cites this paper
• Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells

  2019cites this paper
• Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)

  2018cites this paper
• Preclinical Activity of Metronomic Regimens with Alkylating Agents and Antimetabolites

  2014cites this paper
• Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer

  2013cites this paper